Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Accutane House hearing

Executive Summary

House Energy & Commerce/Oversight Subcommittee is understood to be planning a hearing on a possible link between Roche's Accutane (isotretinoin) and suicide for December. Committee had anticipated holding a hearing this past spring, but refocused its efforts on ImClone (1"The Pink Sheet" Jan. 14, p. 36)...

You may also be interested in...

Accutane safety hearing

House Energy & Commerce/Oversight & Investigations Subcommittee will hold hearing on the possible link between Roche's Accutane and suicide December 11 (1"The Pink Sheet" Oct. 21, In Brief)...

Accutane suicide hearing likely

House Energy & Commerce/Oversight Subcommittee anticipates holding hearing on possible link between Roche's Accutane (isotretinoin) and suicide this spring. Roche has responded to parts of the committee's request for information related to the science behind the acne drug. Charles Bishop, the 15-year old who allegedly committed suicide by crashing an airplane into a Tampa skyscraper, was prescribed Accutane, Tampa police said. Toxicology reports that will determine if Bishop was taking the drug are expected to be complete in about two weeks...

Speedy Approval Of Gilead’s Veklury Sets Stage For Pediatric Expansion, Dosing Refinement

US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts